{"name":"Pedro Cahn","slug":"pedro-cahn","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNRnU3dnpwMGZ2TEI4bDFnckFFcm5za1ZvbUwya3psNXNRZzBTT0ZQcWdfbWlwZTlqLWhMcGE2dlVDUEp0VXdGZ0w1TjNoYVJEdWt6YXFzVmdBWHhtbS13N2FpVkpMSWxGRnB2M1dqMVBsOS1PcFBGSjJMRUR0eWt3eEV5REF4cldleGVqUVJ3dU1lTnU5WFUtb2tTaTk1VHVFSExUR19LZUxQUUk1N2tjLWMxWFIxZjNaZk44X2pDWnZjWFF4c2d6R0lCYlBPLUQ3OVo4UzZQTU1tTG8?oc=5","date":"2020-10-08","type":"trial","source":"European Pharmaceutical Review","summary":"Dolutegravir plus lamivudine shows non-inferior HIV-1 suppression in Phase III trials - European Pharmaceutical Review","headline":"Dolutegravir plus lamivudine shows non-inferior HIV-1 suppression in Phase III trials","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}